Early Immune System Development and Ontogeny (R01 Clinical Trial Optional)
About
The purpose of this Notice of Funding Opportunity (NOFO) is tofurther elucidate the mechanisms of early immune development in utero, during the early post-natal period and during early childhood in neonates, infants, and children and adolescents with or without in-utero exposure to HIV or Anti-Retroviral Therapeutics (ART). This initiative aims to understand intricate mechanisms of immune cells at the maternal-fetal interface, T and B cell development and maturation in offspring, and local immune responses and the role of systemic immunity.
The Early Immune System Development and Ontogeny (R01 Clinical Trial Optional) grant is a federally-funded research opportunity designed for institutions and organizations seeking to advance scientific understanding of early immune system development. This grant supports research examining immune mechanisms in utero, during the early post-natal period, and throughout early childhood in neonates, infants, and children and adolescents. Research may focus on populations with or without in-utero exposure to HIV or Anti-Retroviral Therapeutics (ART). The initiative investigates intricate mechanisms of immune cells at the maternal-fetal interface, T and B cell development and maturation in offspring, and both local and systemic immune responses. Eligible applicants include HBCUs, Hispanic-serving institutions, Asian American Native American Pacific Islander Serving Institutions, Alaska Native and Native Hawaiian Serving Institutions, faith-based and community-based organizations, and eligible federal agencies. This grant is ideal for research institutions and organizations committed to understanding fundamental immunological processes in vulnerable pediatric populations and advancing knowledge that could inform therapeutic interventions and public health strategies.
Funding Facts
● Applications openDeadline
November 5, 2028
Award Amount
Up to $400K
Who can apply
Last verified July 5, 2026 · Source: Grants.gov
Grant Details
Grant Amount
Up to $400K
Deadline
2028-11-05
Grant Type
federal
Application Cycle
Annual deadline (November 5, 2028)
Best For
Research institutions, HBCUs, minority-serving institutions, community-based organizations, and faith-based organizations conducting immunological research
Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Govern
Frequently Asked Questions
Who is eligible for Early Immune System Development and Ontogeny (R01 Clinical Trial Optional)?
Eligible applicants include HBCUs, Hispanic-serving institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Alaska Native and Native Hawaiian Serving Institutions, faith-based organizations, community-based organizations, and eligible federal agencies. For a complete and current list of eligible entity types and any institutional requirements, visit the official funding opportunity announcement on the NIH website.
How much funding does Early Immune System Development and Ontogeny (R01 Clinical Trial Optional) provide?
Funding ranges up to $400,000. Actual award amounts may vary based on the scope of research proposed, project duration, and annual funding cycles. Consult the official funding opportunity for current budget guidelines and any variations by funding year.
How do I apply for Early Immune System Development and Ontogeny (R01 Clinical Trial Optional)?
Applications are submitted through the standard NIH application process via Grants.gov or eRA Commons. Applicants should prepare a detailed research proposal addressing early immune system development mechanisms, budget justification, biographical sketches, and institutional support documentation. The deadline for applications is November 5, 2028. Visit the official NIH Notice of Funding Opportunity (NOFO) for specific submission requirements, formatting guidelines, and detailed instructions.
What can Early Immune System Development and Ontogeny (R01 Clinical Trial Optional) funding be used for?
Funding supports research investigating mechanisms of early immune system development, including maternal-fetal immune interactions, T and B cell development and maturation, local and systemic immune responses, and studies of populations with or without prenatal HIV or ART exposure. Funds may support personnel, equipment, supplies, and other direct research costs outlined in the approved budget. Review the official NOFO for detailed allowable costs and budgeting requirements.
Last updated: July 5, 2026